Activation of human dendritic cells by bacillus Calmette-Guerin

Journal of Urology

Volumn 159, Issue 5, 1998, Pages 1488-1492

  Ramoner, Reinhold ^a   Rieser, Claudia ^a   Herold, Manfred ^a   Klocker, Helmut ^a   Bartsch, Georg ^a   Stenzl, Arnulf ^a   Thurnher, Martin ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Dendritic cells; Interleukin 8; Mycobacterium bovus

Indexed keywords

BCG VACCINE; INTERLEUKIN 8;

ANTIGEN PRESENTATION; ARTICLE; BLADDER TUMOR; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032459748     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199805000-00021     Document Type: Article

References (23)

1. Morales, A., Eidenger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116: 180, 1976.
2. deKernion, J. B.: Immunotherapy of urologic tumors. New York: Churchill Livingstone, p. 1, 1990.
3. Ratliff, T. L.: Role of the immune response in BCG for bladder cancer. Eur. Urol., 2: 17, 1992.
4. Sander, B., Damm, O., Gustafsson, B., Andersson, U. and Hakansson, L.: Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin. J. Urol., 156: 536, 1996.
5. Bettex Galland, M., Studer, U. E., Walz, A., Dewald, B. and Baggiolini, M.: Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guerin administration. Eur. Urol., 19: 171, 1991.
6. Ko, Y. C., Mukaida, N., Ishiyama, S., Tokue, A., Kawai, T., Matsushima, K. and Kasahara, T.: Elevated interleukin-8 levels in the urine of patients with urinary tract infections. Infect. Immunol., 61: 1307, 1993.
7. Austyn, J. M.: New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med., 183: 1287, 1996.
8. Cella, M. Sallusto, F. and Lanzavecchia, A.: Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol., 9: 10, 1997.
9. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B. and Lotze, M. T.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297, 1995.
10. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T. and Storkus, W. J.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87, 1996.
11. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G. and Levy, R.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52, 1996.
12. Murphy, G., Tjoa, B., Ragde, H., Kenny, G. and Boynton, A.: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371, 1996.
13. Thurnher, M., Ramoner, R., Gastl, G., Radmayr, C., Böck, G., Herold, M., Klocker, H. and Bartsch, G.: Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. Int. J. Cancer, 70: 128, 1997.
14. Sallusto, F. and Lanzavecchia, A.: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179: 1109, 1994.
15. Zhou, L. J. and Tedder, T. F.: Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol., 154: 3821, 1995.
16. Matsushima, K., Morishita, K., Yoshimura, T., Lavu, S., Kobayashi, Y., Lew, W., Appella, E., Kung, H. F., Leonard, E. J. and Oppenheim, J. J.: Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med., 167: 1883, 1988.
17. Zhou, L. J. and Tedder, T. F.: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Nat. Acad. Sci., 93: 2588, 1996.
18. van Pelt, L. J., Huisman, M. V., Weening, R.: S., von dem Borne, A. E., Roos, D. and van Oers, R. H.: A single dose of granulocyte-macrophage colony-stimulating factor induces systemic interleukin-8 release and neutrophil activation in healthy volunteers. Blood, 87: 5305, 1996.
19. Christmas, T. J. and Bottazzo, G. F.: Abnormal urothelial HLA-DR expression in interstitial cystitis. Clin. Exp. Immunol., 87: 450, 1992.
20. Inoue, K., Furihata, M., Ohtsuki, Y. and Fujita, Y.: Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis. Virchows Arch., 422: 351, 1993.
21. Zhang, Y., Broser, M., Cohen, H., Bodkin, M., Law, K., Reibman, J. and Rom, W. N.: Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J. Clin. Invest., 95: 586, 1995.
22. Steinman, R. M.: The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol., 9: 271, 1991.
23. + human blood dendritic cells for the active tumor immunotherapy. Exp. Hematol., 25: 232, 1997.